Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.53 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.48 |
| ▸ | ESRRG | P62508 | 5/20 | 0.47 |
| ▸ | ESR1 | P03372 | 3/20 | 0.47 |
| ▸ | ESRRB | O95718 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11457885 | 0.97 | SLC2A1 (0.56) | SLC2A1HRH3CHRNB2CHRNA4ESRRG | |
| SCHEMBL11457025 | 0.89 | SLC2A1 (0.53) | SLC2A1HRH3ESRRGESR1ESRRB | |
| SCHEMBL11448034 | 0.89 | KDM4E (0.51) | SLC2A1HRH3ESRRGESR1ESRRB | |
| SCHEMBL14577990 | 0.87 | LTA4H (0.51) | SLC2A1HRH3CHRNB2CHRNA4ESRRG | |
| SCHEMBL11459353 | 0.86 | CHRNB4 (0.55) | SLC2A1CHRNB2KCNH2 | |
| SCHEMBL11455837 | 0.86 | HRH3 (0.52) | SLC2A1HRH3CHRNB2CHRNA4ESRRG | |
| SCHEMBL13849588 | 0.86 | CHRNB2 (0.60) | CHRNB2CHRNA4 | |
| SCHEMBL11447417 | 0.85 | SLC2A1 (0.55) | SLC2A1HRH3CHRNB2CHRNA4ESRRG | |
| SCHEMBL11448915 | 0.85 | SLC2A1 (0.58) | SLC2A1ESRRGESR1ESRRBKCNH2 | |
| SCHEMBL11466900 | 0.85 | SLC2A1 (0.52) | SLC2A1HRH3CHRNB2CHRNA4ESRRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124624-A1 | SUBSTITUTED 1-AMINOPHTHALAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2009-05-14 | — | — | US | disclosed |
| US-20090124624-A1 | SUBSTITUTED 1-AMINOPHTHALAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2009-05-14 | — | — | US | disclosed |
| US-4225608-A | ANTIDEPRESSANTS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1980-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124624-A1 | SUBSTITUTED 1-AMINOPHTHALAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | AGTR1, AGTR2, AHR | SLC2A1 2814/4885HRH3 165/4885CHRNB2 2603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.